Ost-müük Finch Therapeutics Group, Inc. - FNCH CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.0114 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 0.3695 |
Avatud* | 0.3994 |
Aastane muutus* | -92.41% |
Päeva ulatus* | 0.3495 - 0.3994 |
52 nädala ulatus | 0.30-5.79 |
Keskmine maht (10 päeva) | 116.77K |
Keskmine maht (3 kuud) | 3.48M |
Turukapitalisatsioon | 17.72M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 47.90M |
Tulu | 1.66M |
EPS | -2.24 |
Dividendid (% kasumist) | N/A |
Beeta | -100.00K |
Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 0.3695 | -0.0299 | -7.49% | 0.3994 | 0.3994 | 0.3495 |
Mar 23, 2023 | 0.3994 | 0.0000 | 0.00% | 0.3994 | 0.4006 | 0.3862 |
Mar 22, 2023 | 0.4007 | -0.0187 | -4.46% | 0.4194 | 0.4201 | 0.4006 |
Mar 21, 2023 | 0.4398 | 0.0454 | 11.51% | 0.3944 | 0.4399 | 0.3944 |
Mar 20, 2023 | 0.3965 | -0.0202 | -4.85% | 0.4167 | 0.4195 | 0.3944 |
Mar 17, 2023 | 0.3695 | -0.0100 | -2.64% | 0.3795 | 0.3801 | 0.3661 |
Mar 16, 2023 | 0.3917 | 0.0321 | 8.93% | 0.3596 | 0.3917 | 0.3596 |
Mar 15, 2023 | 0.3844 | -0.0082 | -2.09% | 0.3926 | 0.3926 | 0.3794 |
Mar 14, 2023 | 0.3894 | 0.0399 | 11.42% | 0.3495 | 0.4064 | 0.3495 |
Mar 13, 2023 | 0.3595 | -0.0077 | -2.10% | 0.3672 | 0.3774 | 0.3495 |
Mar 10, 2023 | 0.3596 | -0.0099 | -2.68% | 0.3695 | 0.3695 | 0.3495 |
Mar 9, 2023 | 0.3699 | -0.0495 | -11.80% | 0.4194 | 0.4195 | 0.3698 |
Mar 8, 2023 | 0.4005 | -0.0164 | -3.93% | 0.4169 | 0.4214 | 0.4005 |
Mar 7, 2023 | 0.4096 | 0.0001 | 0.02% | 0.4095 | 0.4194 | 0.3994 |
Mar 6, 2023 | 0.4194 | 0.0090 | 2.19% | 0.4104 | 0.4545 | 0.4104 |
Mar 3, 2023 | 0.4160 | 0.0465 | 12.58% | 0.3695 | 0.4294 | 0.3660 |
Mar 2, 2023 | 0.4044 | 0.0060 | 1.51% | 0.3984 | 0.4044 | 0.3984 |
Mar 1, 2023 | 0.4020 | 0.0026 | 0.65% | 0.3994 | 0.4094 | 0.3894 |
Feb 28, 2023 | 0.4095 | 0.0101 | 2.53% | 0.3994 | 0.4095 | 0.3994 |
Feb 27, 2023 | 0.3996 | 0.0302 | 8.18% | 0.3694 | 0.3996 | 0.3620 |
Finch Therapeutics Group, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | |
---|---|---|---|
Kogutulu | 18.532 | 7.719 | 10.154 |
Tulu | 18.532 | 7.719 | 10.154 |
Kulud, Kokku | 0 | 0.314 | |
Brutokasum | 7.719 | 9.84 | |
Kogu tegevuskulu | 76.69 | 47.155 | 31.296 |
Müük/Üldine/admin kulud, kokku | 21.238 | 14.011 | 7.439 |
Uuringud ja arendus | 57.279 | 33.144 | 23.543 |
Tulud majandustegevusest | -58.158 | -39.436 | -21.142 |
Intressitulud (kulu), muud tulud, neto | 0.022 | 0.106 | 0.488 |
Gain (Loss) on Sale of Assets | 0.028 | -0.013 | -0.14 |
Muud, neto | -0.052 | 0.002 | 0.04 |
Netotulu enne makse | -58.16 | -39.341 | -20.754 |
Netotulu pärast makse | -58.16 | -39.341 | -20.754 |
Netotulu enne erikulusid | -58.16 | -39.341 | -20.754 |
Netotulu | -58.16 | -39.341 | -20.754 |
Arvestatav tulu, v a erikulud | -58.16 | -39.341 | -20.754 |
Arvestatav tulu, koos erikuludega | -58.16 | -39.341 | -20.754 |
Jaotamisele kuuluv netotulu | -58.16 | -39.341 | -20.754 |
Keskmine jaotamisele kuuluv aktsia kohta | 39.2021 | 47.1454 | 47.1454 |
Jaotatav EPS, v a erakorralised kulud | -1.48359 | -0.83446 | -0.44021 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -1.53091 | -0.83419 | -0.43724 |
Ootamatud kulutused (tulu) | -1.827 |
Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
---|---|---|---|---|---|
Kogutulu | 0.138 | 0.361 | 0.354 | 0.806 | 11.343 |
Tulu | 0.138 | 0.361 | 0.354 | 0.806 | 11.343 |
Kogu tegevuskulu | 40.77 | 22.99 | 24.934 | 19.868 | 21.276 |
Müük/Üldine/admin kulud, kokku | 9.584 | 8.164 | 9.404 | 5.065 | 5.739 |
Uuringud ja arendus | 11.859 | 13.923 | 15.53 | 14.803 | 15.537 |
Tulud majandustegevusest | -40.632 | -22.629 | -24.58 | -19.062 | -9.933 |
Intressitulud (kulu), muud tulud, neto | 0.045 | -0.065 | 0.013 | 0.008 | 0.008 |
Muud, neto | 0.216 | 0 | 0 | -0.029 | -0.03 |
Netotulu enne makse | -40.371 | -22.7 | -24.567 | -19.055 | -9.955 |
Netotulu pärast makse | -40.371 | -22.7 | -24.567 | -19.055 | -9.955 |
Netotulu enne erikulusid | -40.371 | -22.7 | -24.567 | -19.055 | -9.955 |
Netotulu | -40.371 | -22.7 | -24.567 | -19.055 | -9.955 |
Arvestatav tulu, v a erikulud | -40.371 | -22.7 | -24.567 | -19.055 | -9.955 |
Arvestatav tulu, koos erikuludega | -40.371 | -22.7 | -24.567 | -19.055 | -9.955 |
Jaotamisele kuuluv netotulu | -40.371 | -22.7 | -24.567 | -19.055 | -9.955 |
Keskmine jaotamisele kuuluv aktsia kohta | 47.7281 | 47.5764 | 47.5289 | 47.5828 | 47.4452 |
Jaotatav EPS, v a erakorralised kulud | -0.84585 | -0.47713 | -0.51688 | -0.40046 | -0.20982 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.44091 | -0.45802 | -0.51688 | -0.40105 | -0.20982 |
Ootamatud kulutused (tulu) | 19.327 | 0.903 | 0 | 0 | |
Gain (Loss) on Sale of Assets | 0 | -0.006 | 0.028 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | |
---|---|---|---|
Käibevarad kokku | 142.551 | 106.164 | 48.626 |
Raha ja lühiajalised investeeringud | 133.481 | 99.71 | 42.186 |
Raha ja ekvivalendid | 133.481 | 99.71 | 42.186 |
Laekumata arved, neto | 0.494 | 1.095 | 4.746 |
Accounts Receivable - Trade, Net | 0.494 | 1.034 | 1.178 |
Prepaid Expenses | 8.576 | 5.359 | 1.694 |
Total Assets | 225.369 | 165.338 | 103.569 |
Property/Plant/Equipment, Total - Net | 24.688 | 7.004 | 3.776 |
Property/Plant/Equipment, Total - Gross | 28.914 | 9.033 | 5.034 |
Accumulated Depreciation, Total | -4.226 | -2.029 | -1.258 |
Goodwill, Net | 18.057 | 18.057 | 18.057 |
Intangibles, Net | 32.9 | 32.9 | 32.9 |
Other Long Term Assets, Total | 7.173 | 1.213 | 0.21 |
Total Current Liabilities | 14.79 | 11.486 | 7.325 |
Accounts Payable | 3.737 | 2.621 | 0.655 |
Accrued Expenses | 11.053 | 5.228 | 3.958 |
Notes Payable/Short Term Debt | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 3.637 | 2.712 |
Total Liabilities | 23.145 | 28.002 | 19.954 |
Total Long Term Debt | 0.007 | 1.808 | 0 |
Long Term Debt | 0 | 1.808 | 0 |
Deferred Income Tax | 3.461 | 3.461 | 3.461 |
Other Liabilities, Total | 4.887 | 11.247 | 9.168 |
Total Equity | 202.224 | 137.336 | 83.615 |
Redeemable Preferred Stock | 233.054 | 143.15 | |
Common Stock | 0.047 | 0.008 | 0.008 |
Additional Paid-In Capital | 363.172 | 7.109 | 3.951 |
Retained Earnings (Accumulated Deficit) | -160.995 | -102.835 | -63.494 |
Total Liabilities & Shareholders’ Equity | 225.369 | 165.338 | 103.569 |
Total Common Shares Outstanding | 47.5122 | 47.1454 | 47.1454 |
Capital Lease Obligations | 0.007 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 122.649 | 142.551 | 156.167 | 177.003 | 198.341 |
Raha ja lühiajalised investeeringud | 106.931 | 133.481 | 149.2 | 168.136 | 193.023 |
Raha ja ekvivalendid | 106.931 | 133.481 | 149.2 | 168.136 | 193.023 |
Laekumata arved, neto | 0.172 | 0.494 | 2.399 | 2.25 | 2.303 |
Accounts Receivable - Trade, Net | 0.172 | 0.494 | 2.399 | 2.245 | 2.251 |
Prepaid Expenses | 15.546 | 8.576 | 4.568 | 6.617 | 3.015 |
Total Assets | 204.633 | 225.369 | 232.979 | 250.328 | 265.951 |
Property/Plant/Equipment, Total - Net | 24.217 | 24.688 | 19.546 | 18.327 | 16.437 |
Property/Plant/Equipment, Total - Gross | 29.773 | 28.914 | 23.094 | 21.237 | 18.835 |
Accumulated Depreciation, Total | -5.556 | -4.226 | -3.548 | -2.91 | -2.398 |
Goodwill, Net | 18.057 | 18.057 | 18.057 | 18.057 | 18.057 |
Intangibles, Net | 32.9 | 32.9 | 32.9 | 32.9 | 32.9 |
Other Long Term Assets, Total | 6.81 | 7.173 | 6.309 | 4.041 | 0.216 |
Total Current Liabilities | 16.787 | 14.79 | 8.851 | 9.524 | 11.503 |
Accounts Payable | 4.765 | 3.737 | 1.382 | 1.719 | 3.878 |
Accrued Expenses | 12.022 | 11.053 | 7.469 | 5.222 | 4.674 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0 | 2.583 | 2.951 | |
Total Liabilities | 24.842 | 23.145 | 13.178 | 22.135 | 26.494 |
Total Long Term Debt | 0 | 0.007 | 0 | 0 | 1.808 |
Long Term Debt | 0 | 0 | 0 | 1.808 | |
Deferred Income Tax | 3.461 | 3.461 | 3.461 | 3.461 | 3.461 |
Other Liabilities, Total | 4.594 | 4.887 | 0.866 | 9.15 | 9.722 |
Total Equity | 179.791 | 202.224 | 219.801 | 228.193 | 239.457 |
Redeemable Preferred Stock | 0 | 0 | 0 | ||
Common Stock | 0.048 | 0.047 | 0.047 | 0.047 | 0.047 |
Additional Paid-In Capital | 365.305 | 363.172 | 361.694 | 360.131 | 356.226 |
Retained Earnings (Accumulated Deficit) | -185.562 | -160.995 | -141.94 | -131.985 | -116.816 |
Total Liabilities & Shareholders’ Equity | 204.633 | 225.369 | 232.979 | 250.328 | 265.951 |
Total Common Shares Outstanding | 47.5591 | 47.5122 | 47.455 | 47.4258 | 47.2273 |
Capital Lease Obligations | 0 | 0.007 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | |
---|---|---|---|
Netotulu/algväärtus | -58.16 | -39.341 | -20.754 |
Raha majandustegevusest | -67.133 | -31.329 | -17.32 |
Raha majandustegevusest | 2.301 | 0.79 | 0.482 |
Mittelikviidsed varad | 3.238 | 3.112 | 0.746 |
Makstud intressid | 0.009 | 0.011 | 0.008 |
Muutused tööjõus | -14.512 | 4.11 | 2.206 |
Tulu investeeringutelt | -15.921 | -2.633 | -0.973 |
Kapitalikulutused | -15.983 | -2.633 | -1.005 |
Muud rahavood investeeringutelt, kokku | 0.062 | 0 | 0.032 |
Rahavood investeeringutelt | 119.11 | 91.475 | 53.3 |
Rahavoogudesse investeerimine | 0.39 | -0.249 | 0 |
Aktsiate emiteerimine (tagasiost), neto | 118.747 | 89.963 | 48.571 |
Laenu väljastamine (kustutamine), neto | -0.027 | 1.761 | 4.729 |
Rahaline kogumuutus | 36.056 | 57.513 | 35.007 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -24.567 | -58.16 | -39.105 | -29.15 | -13.981 |
Cash From Operating Activities | -25.646 | -67.133 | -53.346 | -38.996 | -15.214 |
Cash From Operating Activities | 1.331 | 2.301 | 1.623 | 0.985 | 0.368 |
Non-Cash Items | 2.362 | 3.238 | 0.919 | -0.596 | 0.335 |
Cash Interest Paid | 0.002 | 0.009 | 0.007 | 0.005 | 0.003 |
Changes in Working Capital | -4.772 | -14.512 | -16.783 | -10.235 | -1.936 |
Cash From Investing Activities | -0.909 | -15.921 | -13.919 | -11.555 | -8.824 |
Capital Expenditures | -0.909 | -15.983 | -13.981 | -11.617 | -8.834 |
Other Investing Cash Flow Items, Total | 0 | 0.062 | 0.062 | 0.062 | 0.01 |
Cash From Financing Activities | 0.005 | 119.11 | 119.04 | 118.995 | 117.367 |
Financing Cash Flow Items | 0 | 0.39 | 0.39 | 0.39 | -1.254 |
Issuance (Retirement) of Stock, Net | 0.014 | 118.747 | 118.675 | 118.626 | 118.629 |
Issuance (Retirement) of Debt, Net | -0.009 | -0.027 | -0.025 | -0.021 | -0.008 |
Net Change in Cash | -26.55 | 36.056 | 51.775 | 68.444 | 93.329 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Crestovo Investor LLC | Corporation | 26.3926 | 12641441 | 0 | 2022-04-15 | |
Haft (Nicholas) | Individual Investor | 8.4699 | 4056907 | 63850 | 2022-04-15 | |
Ugwumba (Chidozie) | Individual Investor | 7.3072 | 3500000 | 0 | 2022-04-15 | LOW |
Smith (Mark Burnham) | Individual Investor | 3.9731 | 1903033 | 0 | 2022-04-15 | |
Susquehanna International Group, LLP | Investment Advisor | 3.6972 | 1770858 | 0 | 2022-12-31 | MED |
Smisek (Jeffery A) | Individual Investor | 3.5378 | 1694541 | 1694541 | 2022-04-15 | |
Avenir Management Co, LLC | Investment Advisor | 3.4727 | 1663366 | 0 | 2022-12-31 | LOW |
The Baupost Group, L.L.C. | Investment Advisor/Hedge Fund | 2.1275 | 1019008 | -104100 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1191 | 1015004 | 4870 | 2022-12-31 | LOW |
Bleichroeder LP | Investment Advisor | 1.692 | 810416 | 0 | 2022-12-31 | LOW |
Lake Street Advisors | Investment Advisor | 1.5432 | 739136 | 0 | 2022-12-31 | LOW |
FERRANTE DOMENIC J | Individual Investor | 1.3282 | 636195 | 636195 | 2022-04-15 | |
TRB Advisors LP | Investment Advisor | 1.19 | 570000 | 0 | 2022-12-31 | MED |
SVB Wealth LLC | Investment Advisor | 0.5283 | 253054 | 0 | 2022-12-31 | LOW |
Ikarian Capital LLC | Hedge Fund | 0.496 | 237553 | 0 | 2022-12-31 | HIGH |
Oasis Management Company Ltd. | Investment Advisor/Hedge Fund | 0.4698 | 225000 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4378 | 209710 | -470 | 2022-12-31 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 0.343 | 164267 | 100000 | 2022-12-31 | LOW |
MSD Partners, L.P. | Investment Advisor | 0.3203 | 153397 | -235294 | 2022-12-31 | LOW |
Ballentine Partners, LLC | Investment Advisor/Hedge Fund | 0.2998 | 143603 | 0 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Finch Therapeutics Group, Inc. Company profile
Ettevõttest Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. on kliinilises staadiumis mikrobioomiteraapia ettevõte. Ettevõte kasutab Human-First Discovery platvormi, et arendada suukaudselt manustatavaid bioloogilisi ravimeid. Ettevõte töötab välja ravimeid, mis on mõeldud puuduvate mikroobide ja nende kliiniliselt oluliste biokeemiliste funktsioonide edastamiseks, et korrigeerida düsbioosi ja sellest tulenevaid haigusi. Ettevõtte Human-First Discovery platvorm kasutab pöördtõlgendust, et tuvastada düsbioosiga seotud haigusi ja töötada välja mikrobioomiteraapia, mis neid raviks. Ettevõtte juhtiv tootekandidaat CP101 pakub täielikku mikrobioomi ja seda arendatakse esialgu korduva Clostridioides difficile infektsiooni (CDI) patsientide raviks. Samuti arendab CP101i kroonilise B-hepatiidi viiruse (HBV) raviks. Tooteprogrammi kuuluvad FIN-524, FIN-525 ja FIN-211.
Industry: | Biotechnology & Medical Research (NEC) |
200 Inner Belt Road
SOMERVILLE
MASSACHUSETTS 02143
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com